搜尋結果
2021年6月24日 · Updated: January 3rd, 2021. Written by Dr David Owens. Answer: Of the two available vaccines in Hong Kong BioNTech is the most effective. Both the vaccines available in Hong Kong are very good at preventing death and serious illness against the original SARS-COV-2 virus.
- A Head-to-Head Comparison of the Sinovac and BioNTech Vaccine
Against the original virus BioNTech was 95% effective ...
- A Head-to-Head Comparison of the Sinovac and BioNTech Vaccine
2022年4月19日 · A study by the University of Hong Kong has for the first time compared the effectiveness of China’s Sinovac vaccine with the mRNA vaccine developed by BioNTech against the Omicron variant of...
- Who Can Be Vaccinated?
- Should Pregnant and Breastfeeding Women Be Vaccinated?
- Who Is The Vaccine Not Recommended for?
- Is It Safe?
- How Efficacious Is The Vaccine?
- What Is The Recommended Dosage?
- Is A Booster Dose Recommended For This Vaccine?
- Can This Vaccine Be ‘Mixed and Matched’ with Other Vaccines?
- Does It Prevent Infection and Transmission?
- Does It Work Against New Variants of Sars-Cov-2 Virus?
The vaccine is safe and effective for all individuals aged 18 and above. In line with the WHO Prioritization Roadmap and the WHO Values Framework, older adults, health workers and immunocompromised persons should be prioritised. The Sinovac vaccine can be offered to people who have had COVID-19 in the past. But individuals may choose to delay vacci...
The available data on the Sinovac-CoronaVac (COVID-19) vaccine in pregnant women are insufficient to assess either vaccine efficacy or possible vaccine-associated risks in pregnancy. However, this vaccine is an inactivated vaccine with an adjuvant that is commonly used in many other vaccines with a well-documented safety profile, such as Hepatitis ...
The vaccine is not recommended for persons younger than 18 years of age, pending the results of further studied in that age group. Individuals with a history of anaphylaxis to any component of the vaccine should not take it. Persons with acute PCR-confirmed COVID-19 should not be vaccinated until after they have recovered from acute illness and the...
SAGE has thoroughly assessed the data on quality, safety and efficacy of the vaccine and has recommended its use for people aged 18 and above. Safety data is currently limited for persons above 60 years of age (due to the small number of participants in clinical trials). While no differences in safety profile of the vaccine in older adults compared...
A large phase 3 trial in Brazil showed that two doses, administered at an interval of 14 days, had an efficacy of 51% against symptomatic SARS-CoV-2 infection, 100% against severe COVID-19, and 100% against hospitalization starting 14 days after receiving the second dose.
SAGE recommends the use of Sinovac-CoronaVac vaccine as 2 doses (0.5 ml) given intramuscularly. SAGE recommends that a third, additional dose of the Sinovac vaccine be offered to persons aged 60 and above as part of an extension of the primary series. Current data does not indicate the need for an additional dose in persons under 60 years of age. S...
A booster dose may be considered 4 – 6 months after completion of the primary vaccination series, starting with the higher priority-use groups, in accordance with the WHO Prioritization Roadmap. The benefits of booster vaccination are recognized following increasing evidence of waning vaccine effectiveness against mild and asymptomatic SARS-CoV-2 i...
SAGE accepts two heterologous doses of WHO EUL COVID-19 vaccines as a complete primary series. To ensure equivalent or favourable immunogenicity or vaccine effectiveness either of the WHO EUL COVID-19 mRNA vaccines (Pfizer or Moderna) or the WHO EUL COVID-19 vectored vaccines (AstraZeneca Vaxzevria/COVISHIELD or Janssen) can be used as a second dos...
There is currently no substantive data available related to the impact of COVID-19 vaccine Sinovac-CoronaVac on transmission of SARS-CoV-2, the virus that causes COVID-19 disease. In the meantime, WHO reminds of the need to stay the course and continue practicing public health and social measures that should be used as a comprehensive approach to p...
In an observational study, the estimated effectiveness of Sinovac-CoronaVac in health workers in Manaus, Brazil, where P.1 accounted for 75% of SARS-CoV-2 samples was 49.6% against symptomatic infection (4). Effectiveness has also been shown in an observational study in Sao Paulo in the presence of P1 circulation (83% of samples). There are still i...
2021年6月19日 · Victor Ting. + FOLLOW. Published: 8:00am, 19 Jun 2021. Why you can trust SCMP. A major Hong Kong study has found “substantially higher” levels of antibodies in people vaccinated against Covid-19...
- Victor Ting
2021年8月20日 · SINGAPORE: While her peers were choosing between the Pfizer-BioNTech and Moderna vaccines, 32-year-old Jade Lim made an uncommon choice. Despite having no known allergies to the two vaccines, she...
其他人也問了
How effective is Sinovac vs biontech?
Is Pfizer biontech better than Sinovac?
What is Sinovac & how does it work?
How effective is Sinovac against Omicron?
2020年12月17日 · Efficacy: 94.5 per cent. Rollout: None as of Dec 16. SINOVAC. Developed by China's Sinovac Biotech, the vaccine, known as CoronaVac, is currently undergoing phase 3 clinical trials in places...
